FDA Approves Sotatercept-csrk for Pulmonary Arterial Hypertension
Sotatercept-csrk is the first approved activin signaling inhibitor therapy for pulmonary arterial hypertension, which represents a new class of therapy.
Sotatercept-csrk is the first approved activin signaling inhibitor therapy for pulmonary arterial hypertension, which represents a new class of therapy.
Does remote delivery of psychological therapies reduce pain and disability and improve quality of life in adults with chronic pain?
View Full-Length Video at: https://youtu.be/zVc4kQTWxsURelated Article Available at: https://mayocl.in/48KdoP8
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…
Why do politicians have such a low opinion of British people’s compassion to think this policy is a vote winner, asks Martin McKee Late on…
This chest radiograph (fig 1, left panel) and reconstructed cardiac computed tomography angiography scan (fig 1, right panel) show a rare example of unobstructed supracardiac…
Characterization of microbiome genomes at the species level in over 4,000 metastatic tumor biopsies identifies the distribution and diversity features of tumor-resident bacterial DNA at…
Enjoyment, sadness, disgust, fear and anger are just the beginning of the emotions you can experience
A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated…
Background: Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. Purpose: To evaluate the effectiveness, comparative effectiveness, and harms of…
This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.